US 12,246,002 B2
Pharmaceutical composition for prevention or treatment of circadian rhythm-related disorders, comprising oxyiminomethylbenzene derivative as active ingredient
Gi Hoon Son, Seoul (KR); and Jong Hwa Jung, Daegu (KR)
Assigned to KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION, Seoul (KR); and KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, Daegu (KR)
Appl. No. 17/413,406
Filed by KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION, Seoul (KR); and KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, Daegu (KR)
PCT Filed Sep. 27, 2019, PCT No. PCT/KR2019/012565
§ 371(c)(1), (2) Date Jun. 11, 2021,
PCT Pub. No. WO2020/122380, PCT Pub. Date Jun. 18, 2020.
Claims priority of application No. 10-2018-0160777 (KR), filed on Dec. 13, 2018.
Prior Publication US 2022/0062215 A1, Mar. 3, 2022
Int. Cl. A61K 31/216 (2006.01); A61K 31/22 (2006.01); A61P 3/00 (2006.01); A61P 3/04 (2006.01); A61P 25/00 (2006.01); A61P 25/30 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/216 (2013.01) [A61K 31/22 (2013.01); A61P 3/00 (2018.01); A61P 3/04 (2018.01); A61P 25/00 (2018.01); A61P 25/30 (2018.01); A61P 35/00 (2018.01)] 10 Claims
OG exemplary drawing
 
1. A pharmaceutical composition comprising an oxyiminomethylbenzene derivative or a pharmaceutically acceptable salt thereof,
wherein the oxyiminomethylbenzene derivative is a compound selected from a group consisting of:

OG Complex Work Unit Chemistry
methyl 2-{3-[N-{[3-(trifluoromethyl)phenyl]methoxy}ethanimidoyl]phenoxy}acetate;

OG Complex Work Unit Chemistry
{3-[N-{[3-(trifluoromethyl)phenyl]methoxy}ethanimidoyl]phenoxy}acetic acid;

OG Complex Work Unit Chemistry
methyl 2-(3-{N-[(4-methoxyphenyl)methoxy]ethanimidoyl}phenoxy)acetate;

OG Complex Work Unit Chemistry
(3-{N-[(4-methoxyphenyl)methoxy]ethanimidoyl}phenoxy)acetic acid;

OG Complex Work Unit Chemistry
methyl 2-(3-{N-[(4-nitrophenyl)methoxy]ethanimidoyl}phenoxy)acetate; and

OG Complex Work Unit Chemistry
(3-{N-[(4-nitrophenyl)methoxy]ethanimidoyl}phenoxy)acetic acid.